A study by Giannelli et al (34) indicated that the inhibition of TGF-β signalling resulted in numerous downstream effects, which may improve clinical outcomes in hepatocellular carcinoma treatment. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.